114 related articles for article (PubMed ID: 1539199)
1. Posttransplant renal allograft dysfunction as a prognostic factor in triple therapy-treated patients.
Pallardó LM; García J; Sánchez J; Górriz JL; Orero E; Calabuig F
Transplant Proc; 1992 Feb; 24(1):113-4. PubMed ID: 1539199
[No Abstract] [Full Text] [Related]
2. Late acute rejection in renal transplant recipients: response to steroid treatment.
Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
[No Abstract] [Full Text] [Related]
3. Five-year experience with a triple drug protocol in renal transplantation.
Pallardó LM; Sánchez J; García J; Puig N; Sánchez P; Górriz JL; Cruz JM
Transplant Proc; 1992 Feb; 24(1):56-7. PubMed ID: 1539342
[No Abstract] [Full Text] [Related]
4. The influence of cold ischemia and donor age on renal allograft outcome in the cyclosporine era.
Cacciarelli TV; Sumrani N; DiBenedetto A; Hong JH; Sommer BG
Transplant Proc; 1992 Oct; 24(5):2044-5. PubMed ID: 1412966
[No Abstract] [Full Text] [Related]
5. Triple drug maintenance therapy in renal transplantation.
Pallardó LM; Sánchez J; Hernandez M; Górriz JL; Sánchez P; Beneyto I; Rochera A
Transplant Proc; 1992 Feb; 24(1):58-9. PubMed ID: 1539343
[No Abstract] [Full Text] [Related]
6. Renal allograft rejection in a patient with the Wiskott-Aldrich syndrome.
Meisels IS; Strom TB; Roy-Chaudhury P; Abrams J; Shapiro ME
Transplantation; 1995 Apr; 59(8):1214-5. PubMed ID: 7732568
[No Abstract] [Full Text] [Related]
7. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
[No Abstract] [Full Text] [Related]
8. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
9. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
[No Abstract] [Full Text] [Related]
10. Delayed graft function is associated with an increased incidence of occult rejection and results in poorer graft survival.
Howard RJ; Pfaff WW; Brunson ME; Ramos EL; Peterson JC; Croker BP; Scornik JC; Parris CJ; Fennell RS
Transplant Proc; 1993 Feb; 25(1 Pt 2):884. PubMed ID: 8442256
[No Abstract] [Full Text] [Related]
11. Analysis of the risk factors of late failure in renal transplantation under cyclosporine immunosuppression.
Pallardó LM; Sánchez P; Sánchez J; García J; Beneyto I; Orero E; Rochera A
Transplant Proc; 1994 Oct; 26(5):2536-7. PubMed ID: 7940781
[No Abstract] [Full Text] [Related]
12. Living-related and living-unrelated kidney transplantation using low-dose triple immunosuppression.
Francis DM; Walker RG; Millar RJ; Becker G
Transplant Proc; 1992 Oct; 24(5):1887-8. PubMed ID: 1412899
[No Abstract] [Full Text] [Related]
13. Posttransplant serum creatinine area under the curve predicts renal allograft outcome.
Sumrani N; Hong J; Miles A; Markell M; Distant D; Fleishhacker J; Maursky V; Jean-Baptiste F; Sommer B
Transplant Proc; 1996 Feb; 28(1):356-7. PubMed ID: 8644260
[No Abstract] [Full Text] [Related]
14. Double-therapy vs triple-therapy immunosuppression in cadaveric renal transplants.
Carmellini M; Romagnoli J; Pietrabissa A; Di Stefano R; Oleggini M; Rindi P; Rizzo G; Mosca F
Transplant Proc; 1994 Oct; 26(5):2546-7. PubMed ID: 7940785
[No Abstract] [Full Text] [Related]
15. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
[No Abstract] [Full Text] [Related]
16. Cytokine-release syndrome: differences between high and low doses of OKT3.
Norman DJ; Kimball JA; Barry JM
Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
[No Abstract] [Full Text] [Related]
17. Cyclosporine monotherapy versus conventional therapy in the living-related renal transplant: a one center retrospective study.
Masri MA; Shakuntala V; Dhawan IK; Zahir M; Shanwaz M; Hayes K; Pingle A
Transplant Proc; 1993 Jun; 25(3):2248-9. PubMed ID: 8516889
[No Abstract] [Full Text] [Related]
18. Optimization of cyclosporine monotherapy--long-term graft function.
Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
[No Abstract] [Full Text] [Related]
19. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684
[No Abstract] [Full Text] [Related]
20. Infections after renal transplantation.
Ko KS; Cho DO; Ahn JH; Lee TW; Ihm CG; Chang SG; Chai SE; Park HC; Hong SH; Joo HZ
Transplant Proc; 1994 Aug; 26(4):2072-4. PubMed ID: 8066674
[No Abstract] [Full Text] [Related]
[Next] [New Search]
